Join the 'Kovaltry' group to help and get support from people like you.
FDA Approves Bayer's Kovaltry (Antihemophilic Factor (Recombinant)) for the Treatment of Children and Adults with Hemophilia A
Posted 18 Mar 2016 by Drugs.com
WHIPPANY, N.J., March 17, 2016 /PRNewswire/ – The U.S. Food and Drug Administration has approved Bayer's Kovaltry Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and adults. The approval is based on results from the LEOPOLD (Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease) clinical trials, ...